Please ensure Javascript is enabled for purposes of website accessibility

New Investor? 2 Smart Stocks to Buy Right Now

By Trevor Jennewine – Sep 28, 2021 at 7:44AM

Key Points

  • The S&P 500 has delivered an annualized return of 7.7% since 2001.
  • Teladoc makes healthcare more convenient and less expensive.
  • UiPath helps enterprises automate a variety of business processes.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These growth stocks could help you beat the market.

Whether you're a new investor or a seasoned professional, there is only one reason to buy individual growth stocks: You want to beat the market. And that's no small task. Over the last 20 years, the S&P 500 has surged 344%, representing an annualized return of 7.7%. Topping that figure won't be easy, but it is possible. 

So what's the secret? A long-term mindset is one of the most important tools at a retail investor's disposal. That means you should look for high-quality stocks you feel comfortable holding for at least five years. It's also important to build a diversified portfolio, meaning you should aim to own at least 25 different stocks.

Here are two ideas to get you started.

Two young investors working side by side at the computer.

Image source: Getty Images.

1. Teladoc Health

Teladoc (TDOC 2.42%) is disrupting the multi-trillion dollar healthcare industry. Its virtual-first platform connects patients with healthcare professionals, allowing them to attend appointments from the comfort of their own homes. More importantly, Teladoc leans on a provider network of over 50,000 clinicians, with expertise in over 450 sub-specialties, making it the most comprehensive telehealth solution available.

To reinforce that advantage, Teladoc acquired Livongo Health last year. Livongo specializes in chronic conditions like diabetes and hypertension. Specifically, the company collects data from its devices (e.g. blood glucose meters, blood pressure cuffs), then provides patients with AI-powered nudges and personalized guidance from health coaches.

In acquiring Livongo, Teladoc expanded its offering to include the remote management of chronic conditions, and it brought Livongo's prodigious data in-house, bolstering its own AI models. As Teladoc continues to add new members and collect more data, its ability to drive better health (and cost) outcomes should be a growth driver for the business.

Financially, Teladoc has delivered an impressive top-line performance in recent years.

Metric

Q2 2019 (TTM)

Q2 2021 (TTM)

CAGR

Revenue

$492.6 million

$1.6 billion

82%

Source: YCharts. TTM = trailing-12-months. CAGR = compound annual growth rate.

During the most recent quarter, Teladoc's U.S. memberships grew by just 1%, a sharp deceleration from the 92% growth in the prior year. As a result, the stock currently sits 50% below its all-time high. But I think that overreaction creates a buying opportunity for long-term investors.

Last year, the average time between a member's request and a telehealth appointment was just 10 minutes. And Teladoc's virtual platform saves clients $472 per visit compared to alternative solutions, according to Veracity Analytics. Put another way, Teladoc makes healthcare faster, cheaper, and more convenient. And as more patients become comfortable with the idea of engaging with clinicians remotely, I think Teladoc will see strong demand from employers, insurance companies, and health systems.

That's why this growth stock looks like a smart buy right now.

2. UiPath

In 1980, Microsoft CEO Bill Gates expressed his vision for the future with these words: "A computer on every desk and in every home." That may seem antiquated in hindsight, but it was an ambitious goal at the time. And today, UiPath (PATH -2.57%) has a similarly ambitious goal: a robot for every person.

Specifically, its platform helps clients build and deploy software robots capable of automating a variety of business processes. To do this, UiPath leans on robotic process automation (RPA), a technology that makes it possible to automate repetitive tasks like syncing databases, completing forms, and moving files.

However, UiPath goes beyond simple RPA, infusing its software with various forms of artificial intelligence, including computer vision, natural language processing, and machine learning. In short, this empowers its bots to handle more complicated tasks, such as understanding documents, engaging in conversations, and making complex decisions. More importantly, these bots have the ability to learn from human behavior, meaning they become more intelligent over time.

This industry is still in its nascent stages, but UiPath has already claimed the top spot. Forrester Research recently recognized the company as the RPA industry leader, citing a stronger current offering and a stronger growth strategy than any of its rivals.

That advantage has helped UiPath grow its business quickly.

Metric

Q2 2021 (TTM)

Q2 2022 (TTM)

CAGR

Customers

7,000

9,100

30%

Revenue

$451.2 million

$736.9 million

63%

Source: UiPath SEC filings, Ycharts. TTM = trailing-12-months. CAGR = compound annual growth rate. Note: Q2 2022 ended July 31, 2021.

During the most recent quarter, UiPath posted a retention rate of 144%, meaning the average customer spent 44% more over the past year. That demonstrates the stickiness of UiPath's platform, suggesting that clients find it so valuable that they are actually spending more over time.

Looking ahead, the company is well-positioned to maintain that momentum. Management puts its market opportunity at $60 billion, and given UiPath's industry-leading position, this tech company should benefit from strong adoption as more enterprises aim to drive efficiency through automation. That's why this growth stock looks like a solid inivestment right now.

Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool’s board of directors. Trevor Jennewine owns shares of UiPath Inc. The Motley Fool owns shares of and recommends Microsoft, Teladoc Health, and UiPath Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

UiPath Inc. Stock Quote
UiPath Inc.
PATH
$11.77 (-2.57%) $0.31
Microsoft Stock Quote
Microsoft
MSFT
$240.33 (-0.59%) $-1.43
Teladoc Health Stock Quote
Teladoc Health
TDOC
$27.13 (2.42%) $0.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.